Statement on human papillomavirus DNA test utilization.

Department of Health and Human Services, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Rockville, MD 20852, USA. ds87v
Archives of pathology & laboratory medicine (Impact Factor: 2.88). 09/2009; 133(8):1276-7. DOI: 10.1043/1543-2165-133.8.1276
Source: PubMed


Available from: Diane Davis Davey, Jan 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: This statement from the Cytopathology Education and Technology Consortium summarizes appropriate and inappropriate uses of human papillomavirus testing in cervical cancer screening based on guidelines from the American Society for Colposcopy and Cervical Pathology and the American Cancer Society. © 2014 S. Karger AG, Basel.
    Acta cytologica 02/2014; 42(5). DOI:10.1159/000358795 · 1.56 Impact Factor
  • Source
    British Journal of Cancer 09/2011; 105(7):877-80. DOI:10.1038/bjc.2011.351 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral HPV infection elevates risk of oropharyngeal cancer, but its natural history is unknown. Natural history studies necessitate validation of an automated, high-throughput method for HPV genomic DNA detection in oral rinse samples (ORS). To compare agreement of oral HPV detection in ORS processed by a magnetic-bead based automated platform to a previous gold-standard, manual protein-precipitation method. Agreement was compared to that of repeat sampling and repeat HPV testing. HIV-infected individuals (n=100) provided two ORS collected 15 min apart. DNA was isolated from equal aliquots by either a protein-precipitation based (Puregene, Qiagen) or magnetic bead-based (QIAsymphony™ SP, Qiagen) method. HPV DNA was detected and type-specified by consensus primer PCR and reverse line blot hybridization. The kappa statistic was used to assess overall agreement (OA) and agreement on a positive test (Ps+). The DNA purification methods had very high agreement for categorizing an individual as HPV infected (OA=0.95; Ps+=0.94) as well as for detection of HPV type-specific infection (OA=0.99; Ps+=0.88) in ORS. Agreement for detection of HPV type-specific infection was greater than that observed with repeat oral rinse sampling (OA=0.99, Ps+=0.76) but comparable to inter-assay agreement (OA=1.00, Ps+=0.90). HPV detection in ORS processed with a magnetic-bead based automated platform will facilitate large natural history studies of oral HPV infection necessary to evaluate the potential use of oral HPV detection in oral cancer screening.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 04/2011; 50(4):270-5. DOI:10.1016/j.jcv.2010.12.005 · 3.47 Impact Factor